Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
enVVeno Medical Corp(NVNO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NVNO
09/28/2026: NVNO (1-star) is currently NOT-A-BUY. Pass it for now.
enVVeno Medical Corp is a clinical-stage medical device firm primarily focused on developing the VenoValve, a surgical solution for chronic venous insufficiency. Its main strength lies in its specialized, potentially breakthrough technology that addresses a large patient segment currently lacking adequate deep vein treatment options. The company's growth story is tied to successful clinical outcomes and eventual FDA approval. Risks include high cash burn, the absence of commercial revenue, and the competitive threat from established medical device incumbents. The stock may suit growth-oriented, high-risk investors who monitor clinical trial results and regulatory news as the primary drivers of long-term value.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical outcomes rather than current growth metrics. |
| Momentum investor | Strong fit while signal remains positive | Investors often trade the stock based on clinical trial updates and news flow regarding regulatory milestones. |
| Value investor | Weak fit | The lack of revenue and negative earnings make it unsuitable for traditional value-based valuation methodologies. |
| Dividend investor | Weak fit | The company is in an early growth phase and does not generate the cash flow required to support dividends. |
| Low-risk investor | Weak fit | The binary nature of clinical outcomes and high cash burn create significant volatility and risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial news and speculative sentiment. |
| Valuation risk | High | As a pre-revenue company, valuation is largely subjective and based on long-term potential. |
| Competition risk (Medtech incumbents) | High | Large, established players have significantly more resources to defend their market share. |
| Business quality | Medium | The company holds promising intellectual property but lacks a proven commercial business model. |
| Dividend income | Low / none | There is no current or expected dividend income. |
| Execution risk | High | Successfully navigating FDA approval and achieving commercial adoption are high-bar operational challenges. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -26.51% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.02M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 22.2K shares | Beta 1.07 | 52 Weeks Range 7.01 - 35.17 | Updated Date 09/27/2026 |
52 Weeks Range 7.01 - 35.17 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.97 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Venous Intervention Research | Clinical stage research and development of the VenoValve. | The company does not currently sell products and earns no revenue; investors are betting on the success of future technology. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value -14.96M | Price to Sales(TTM) 216.91 |
Enterprise Value -14.96M | Price to Sales(TTM) 216.91 | ||
Enterprise Value to Revenue 274.86 | Enterprise Value to EBITDA -0.87 | Shares Outstanding 694.83K | Shares Floating 590.41K |
Shares Outstanding 694.83K | Shares Floating 590.41K | ||
Percent Insiders 8.23 | Percent Institutions 15.96 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About enVVeno Medical Corp
Exchange NASDAQ | Headquarters Irvine, CA, United States | ||
IPO Launch date 2018-05-31 | CEO & Director Mr. Robert A. Berman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 33 | Website https://www.envveno.com |
Full time employees 33 | Website https://www.envveno.com | ||
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.